MISSISSAUGA, ON, June 7, 2013 /CNW/ - MedX Health Corp., (TSXV.MDX) a global leader in drug free, non-invasive low level laser light therapy
for tissue repair and pain relief have reported their revenues for 2012
and the first quarter of 2013. Please see www.SEDAR.com for the actual filings.
About MedX Health Corp.
MedX is a twelve (12) year old Canadian company, headquartered in
Mississauga, Ontario (Toronto), and is a global leader in the design,
manufacturing and distribution of quality low level laser and light
therapy technologies for use in numerous medical settings, including
rehab/chiropractic, dental, wound care, and veterinary medicine,
providing patients with drug free and non-invasive treatment of tissue
damage and pain. MedX laser and light products are FDA approved, Health
Canada cleared, and CE Mark approved for use in North America as well
as the European Union. MedX Health acquired the worldwide assets of
MoleMate in June, 2011. For a complete profile of MedX Health Corp. and
its products visit www.medxhealth.com.
About MoleMate Imaging and Skin Cancer
MoleMate recently received approval from Health Canada, and is
immediately available and in stock for all Canadian physicians, joining
their colleagues in Europe, the UK, Australia, and the US, who have
been utilizing this new pain-free, non-invasive imaging system to 'See
More', approximately 2mm below the surface of suspicious moles, and
provide additional information and images related to every mole and all
types of melanomas and non-melanomas.
MoleMate uses a patented device and technology that features a hand-held
scanner designed for office use that utilizes light to view beneath
suspicious moles or lesions in a pain free, non-invasive manner,
creating images for physicians to evaluate all types of moles and
lesions within seconds, providing images that can reveal if a mole is
benign, or something more serious, often eliminating the need for skin
biopsies, resulting in less pain, scarring, and expense. Physicians
interested in learning more should contact MedX Health Corp. at www.simsys-molemate.com.
This press release does not constitute an offer of any securities for
sale. This press release contains certain forward-looking statements
within the meaning of applicable Canadian securities legislation. These
forward-looking statements involve certain risks and uncertainties that
could cause actual results to differ, including, without limitation,
the company's limited operating history and history of losses, the
inability to successfully obtain further funding, the inability to
raise capital on terms acceptable to the company, the inability to
compete effectively in the marketplace, the inability to complete the
proposed acquisition and such other risks that could cause the actual
results to differ materially from those contained in the company's
projections or forward-looking statements. All forward-looking
statements in this press release are based on information available to
the company as of the date hereof, and the company undertakes no
obligation to update forward-looking statements to reflect events or
circumstances occurring after the date of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this press release.
SOURCE: MedX Health Corp.
For further information:
Steve Guillen / President and Chief Executive Officer
MedX Health Corp. email@example.com
Phone: (905) 670-4428